Cemiplimab significantly improved disease-free survival in high-risk CSCC patients, with a 24-month survival rate of 87% compared to 64% for placebo. The phase 3 C-POST trial showed cemiplimab's ...

Phase 3 randomized trial (KEYNOTE-630) of adjuvant pembrolizumab (pembro) versus placebo (pbo) for high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) following surgery and ...

The median disease-free survival was not reached in the cemiplimab arm and was 49.4 months in the placebo arm. Adjuvant cemiplimab can improve disease-free survival (DFS) in patients with cutaneous ...

Regeneron Pharmaceuticals announced promising results from the Phase 3 C-POST trial of Libtayo (cemiplimab), a PD-1 inhibitor for patients with high-risk cutaneous squamous cell carcinoma (CSCC) ...

Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo. The Food and Drug Administration (FDA) has approved Libtayo ® (cemiplimab-rwlc) for the ...

Regeneron’s phase 3 trial of the LAG-3 inhibitor fianlimab plus cemiplimab failed to meet its primary endpoint of progression-free survival in first-line advanced melanoma.

Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: Results from a global multi-site chart review. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

Clinicians must consider patient comorbidities and therapy safety when selecting immunotherapy for cSCC, says Todd Schlesinger, MD. Specifically, he highlighted differences in mechanisms of action ...

In a pretreated population of participants with advanced/metastatic cancer and the majority with prior PD-(L)1 treatment, BHV-1510 2.5 mg/kg Q3W plus cemiplimab resulted in confirmed objective ...